

Hot Topics in Renal Cell Carcinoma: what we know and looking to the future
Aula Magna Dental School-Università di Torino
Via Nizza 230-Torino
19 June 2026

Responsabile scientifico

Dott.ssa Sara Elena Rebuzzi
Prof. Marco Oderda

Scientific Committee

Prof. Paolo Gontero
Prof. Massimo Di Maio
Prof. Umberto Ricardi
Dott. Massimiliano Icardi

- 8.30 Welcome of the Authorities **Mario Airoidi, Alessandro Comandone, Massimo Aglietta**
8.45 Welcome and introduction to the congress **Sara Elena Rebuzzi, Marco Oderda**

IMAGING AND PATHOLOGY

Chairs: **Silvia Morbelli, Isabella Castellano,**

- 9.00 Novel imaging (PET) **Alessio Rizzo**
9.10 Anatomopathological classification
9.20 Translational characterization and biomarkers **Pasquale Rescigno**
9.30 Discussion

LOCALIZED RCC – SURGERY

Chairs: **Paolo Gontero, Marco Allasia, Alessandro Volpe**

- 9.45 Partial nephrectomy with single-port robot **Paolo Gontero**
9.55 3D models to guide surgery: an indulgence or a requirement? **Marco Oderda**
10.05 Cytoreductive nephrectomy and nephrectomy with IVC thrombectomy: what to expect?
Giuseppe Simone
10.15 Adjuvant pembrolizumab after partial nephrectomy: is all that glitters gold? **Riccardo Campi**
10.25 Discussion

10.45 – 11.15 Coffee break

LOCALIZED RCC – ABLATIVE THERAPY

Chairs: **Umberto Ricardi, Alessandra Mosca, Carlo Gazzera**

- 11.15 Ablative therapies **Marco Calandri**
11.25 Radiotherapy **Giuseppe Carlo Iorio**
11.35 Oligometastatic tumor and strategies **Francesco Di Stefano**
11.45 Discussion

LOCALIZED RCC – SYSTEMIC THERAPY

Chairs: **Massimo Di Maio, Giuseppe Procopio, Marcello Tucci**

12.00 Adjuvant therapy **Roberto Filippi**

12.10 Relapse after adjuvant therapy **Alessia Mennitto**

12.20 Patients' selection and clinical case **Marco Maruzzo, Veronica Prati**

12.40 Discussion

13.00 – 14.00 Lunch break

METASTATIC RCC – 1st line

Chairs: **Massimiliano Icardi, Sara Elena Rebuzzi, Giuseppe Fornarini**

14.00 Prognostic factors and classification **Davide Bimbatti**

14.10 Systemic therapy ccRCC: state of the art

14.25 Systemic therapy nccRCC: state of the art **Giuseppe Procopio**

14.40 Patients' selection and clinical case **Sebastiano Buti, Cecilia Nasso**

15.00 Discussion

RCC – Further lines and beyond

Chairs: **Marco Maruzzo, Cinzia Ortega, Consuelo Buttigliero**

15.20 Systemic therapy in the \geq 2nd line: state of the art **Francesca Vignani**

15.30 Sequence algorithm **Ilaria Depetris**

15.40 Real World Data **Sara Elena Rebuzzi**

15.50 Future Strategies **Giuseppe Luigi Banna**

16.00 Discussion

16.20 -16.30 Closing remarks **Paolo Gontero, Massimiliano Icardi, Sara Elena Rebuzzi, Marco Oderda**

RAZIONALE

Renal cell carcinoma is a highly heterogeneous and evolving disease that continues to pose significant diagnostic and therapeutic challenges. Advances in imaging and pathology are refining tumor characterization, while innovations in surgery, ablative approaches, radiotherapy, and systemic treatments are reshaping clinical practice across both localized and advanced settings.

This congress aims to offer a comprehensive and up-to-date overview of these developments, combining evidence-based insights with expert perspectives and real-world experience. By addressing key controversies, highlighting emerging data, and exploring future directions, the meeting seeks to support clinicians in optimizing decision-making and delivering increasingly personalized and effective care for patients with renal cell carcinoma.